Novo Nordisk CEO Mike Doustdar discussed the company's GLP-1 weight-loss drug Wegovy in an interview with Bloomberg's Katie Greifeld, revealing that over 246,000 people are now taking the medication. The conversation covered supply chain challenges, pricing strategies, and the company's ongoing lawsuit against Hims over alleged copycat obesity drugs.

Doustdar addressed the explosive demand for Wegovy, which has created supply constraints as the company works to increase production capacity. The CEO explained how Novo Nordisk is balancing accessibility with profitability while managing the complex logistics of scaling up manufacturing for this breakthrough medication. The discussion also touched on how the company determines pricing for a drug that has become central to obesity treatment.

The lawsuit against Hims highlights the competitive pressures in the GLP-1 market as other companies attempt to capitalize on Wegovy's success. Novo Nordisk is taking legal action to protect its intellectual property and market position as demand continues to surge. The interview provided insight into how the pharmaceutical giant is navigating both the business and regulatory challenges of this rapidly evolving therapeutic category.